Treatment of lentigo maligna with tazarotene 0.1% gel

We report 2 elderly patients with facial lentigo maligna who experienced complete regression, both clinically and histopathologically, after once-daily topical treatment with tazarotene 0.1% gel for 6 to 8 months. After a follow-up period of 18 and 30 months, no recurrence was observed. We believe t...

Full description

Saved in:
Bibliographic Details
Published inJournal of the American Academy of Dermatology Vol. 50; no. 1; pp. 101 - 103
Main Authors Chimenti, Sergio, Carrozzo, Anna Maria, Citarella, Luigi, De Felice, Catia, Peris, Ketty
Format Journal Article
LanguageEnglish
Published New York, NY Mosby, Inc 2004
Elsevier
Subjects
Aged
Aged, 80 and over
Biological and medical sciences
Dermatologic Agents - administration & dosage
Dermatology
Female
Gels
Humans
Hutchinson's Melanotic Freckle - drug therapy
Male
Medical sciences
Nicotinic Acids - administration & dosage
Pigmentary diseases of the skin
Tumors of the skin and soft tissue. Premalignant lesions
Human
Skin disease
Premalignant lesion
Pigmentation disorder
Dermatology
Retinoid
Antipsoriatic agent
Malignant tumor
Dubreuilh precancerous melanosis
Case study
Local administration
Chemotherapy
Treatment
Tazarotene
Malignant melanoma
Online AccessGet full text

Cover

More Information
Summary:We report 2 elderly patients with facial lentigo maligna who experienced complete regression, both clinically and histopathologically, after once-daily topical treatment with tazarotene 0.1% gel for 6 to 8 months. After a follow-up period of 18 and 30 months, no recurrence was observed. We believe that tazarotene might be considered as an alternative medical approach in selected patients with lentigo maligna.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:0190-9622
1097-6787
DOI:10.1016/j.jaad.2003.07.005